Yaron Daniely, PhD

Head of aMoon Alpha

Yaron Daniely, PhD
play podcast pause podcast
equalizer
equalizer-active

Yaron Daniely, PhD

Head of aMoon Alpha

Yaron Daniely is the Head of aMoon Alpha, an internal value creation unit charged with translating aMoon’s unique scale, talent and global network into concrete competi-tive advantages and growth opportunities for our portfolio companies. He is also an investment leader at aMoon Velocity, our early stage investment fund that pursues dis-ruptive, cutting-edge technologies with the potential to accelerate cure.

Born in Israel and raised in Florida, Yaron was fascinated by science, medicine and tech-nology from a young age. Driven by a passion for discovering and creating novel solu-tions, and a persistent quest for challenging the status quo wherever he went, Yaron spent much of his career leading innovative health tech companies. He brings to aMoon a wealth of hands-on experience as a business leader in both the private and public sec-tors. In return, aMoon fulfills his craving for cutting-edge science and strategic thinking, applied to the creation and mentorship of young companies focused on impacting people’s health.

Prior to aMoon, Yaron was the President and CEO of Yissum, Hebrew University’s ac-claimed Technology Transfer Company, and Co-Chairperson of the Israel Technology Transfer Network (ITTN), where he converted academic research into practical prod-ucts and technologies. Before leading Yissum, he spent 14 years as a senior executive - and 10 years as CEO - of private and NASDAQ-traded Biopharma and Biotech compa-nies. He also co-founded and served for ten years as the director of Israel's first and leading MBA program for professionals of the local Biomedical industry at the College of Management Academic Studies.

Yaron earned his PhD from the Sackler Institute of Graduate Biomedical Sciences at the NYU School of Medicine. Following his doctoral program, he served as a Visiting Fel-low at the NIH, and as an American Cancer Society Postdoctoral Fellow in the Depart-ment of Molecular Cell Biology at The Weizmann Institute for Science in Israel. He also holds an MBA from the Technion - Israel Institute of Technology.

Investments